KOREA study (Korea Osimertinib Real world Evidence study to Assess safety and efficacy)

Trial Identifier: D5160R00009
Sponsor: AstraZeneca
NCTID:: NCT02777567
Start Date: September 2016
Primary Completion Date: March 2020
Study Completion Date: March 2020
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
South Korea, South Korea South Korea, South Korea